New prostate cancer EPCA

Fall 2006 CSANews Issue 60  |  Posted date : May 30, 2007.Back to list

Recent studies show that a new cancer antigen-2 (EPCA-2) blood test may be more effective in detecting prostate cancer than the currently used prostate-specific antigen (PSA) test.

Research indicates that the EPCA-2 blood test appears to detect prostate cancer earlier and more accurately than the standard PSA testing methods. The PSA test remains a topic of debate, as it often misdiagnoses the cancer; in some men, the PSA test finds signs of cancer when there is simply an infection. In other men, the PSA may fail to detect any problems when cancer may indeed be present.

When tested on 330 men, researchers found that the EPCA-2 test was 97% effective in identifying men without cancer, and 94% effective in detecting those with the disease. The PSA test, in comparison, detected cancer in only 85% of men with the disease. Furthermore, the new EPCA-2 test appears to detect whether the cancer has spread beyond the prostate – a majorfactor to consider when prescribing cancer treatment.